NCT06240039Active, not recruiting
Direct Versus Indirect Effect of Amino Acids on Hepatokines
Direct Versus Indirect Effect of Amino Acids on Hepatokines in Healthy Subjects and Patients With Non-alcoholic Fatty Liver Disease
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
Liver hormones are key metabolic regulators and increased in metabolic diseases, including fatty liver disease. The underlying mechanisms driving the elevated levels are currently unknown and presents a major challenge in understanding the interplay between liver hormones and fatty liver disease. The project aims to investigate what stimulates the liver to secrete its hormones and why the secretion is increased in patients with fatty liver disease. The investigator (Associate Prof. Nicolai J Wewer Albrechtsen) will investigate the direct and indirect effects of an amino acid amino infusion on the secretion of hepatokines in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD).
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 25 Jan 2024
- Start date
- 11 Feb 2024
- Primary completion date
- 16 Apr 2025
- Lead sponsor
- University of Copenhagen
- Diseases
- Obesity, Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06240039
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 11 Feb 2024 to the primary completion date, 16 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe liver disease (estimated by FIB4 score \> 3.25)
- Type 2 diabetes according to ADA criteria
- Significant history of alcoholism or drug/chemical abuse as per investigators judgement
- Amino acid related diseases
- Kidney disease
- Cardiac problems
- Cancer within the past 1 year
- Any medicine, acute illness (within the last two weeks) or other circumstances that in the opinion of the investigator might endanger the participants' safety or compliance with the protocol
- Group 2 (individuals with hepatic steatosis):
- Severe liver disease (estimated by FIB4 score \> 3.25)
- Type 2 diabetes according to ADA criteria
- Significant history of alcoholism or drug/chemical abuse as per investigators judgement
- Amino acid related diseases
- Kidney disease
- Cardiac problems
- Cancer within the past 1 year
- Any medicine, acute illness (within the last two weeks) or other circumstances that in the opinion of the investigator might endanger the participants' safety or compliance with the protocol
Other
- Contraindications for MRI-scan
- Anemia
- Pregnancy or breast feeding
- Smoking
- Contraindications for MRI-scan
- Anemia
- Pregnancy or breast feeding
- Smoking
Who the study is looking for
- Male or female between 25-65 years of age at time of screening
- Body mass index of 18.6-25 kg/m2
- Male or female between 25-65 years of age at time of screening
- Body mass index of 25-40 kg/m2
- Hepatic non-alcoholic steatosis verified by liver biopsy, fibroscan or ultrasound
Criteria the registry did not label
- Group 1: (Lean controls)
Age in the registry: 25 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bispebjerg University Hospital Coordinator of this site? Confirm its status | Copenhagen | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.